Literature DB >> 18817363

Structure-activity relationships in 1,4-benzodioxan-related compounds. 9. From 1,4-benzodioxane to 1,4-dioxane ring as a promising template of novel alpha1D-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents.

Wilma Quaglia1, Alessandro Piergentili, Fabio Del Bello, Yogita Farande, Mario Giannella, Maria Pigini, Giovanni Rafaiani, Antonio Carrieri, Consuelo Amantini, Roberta Lucciarini, Giorgio Santoni, Elena Poggesi, Amedeo Leonardi.   

Abstract

Novel 1,4-dioxane compounds structurally related to WB 4101 (1) were prepared in order to investigate the possibility that the quite planar 1,4-benzodioxane template of 1 might be replaced by the less conformationally constrained 1,4-dioxane ring. The biological profiles of the new compounds were assessed using binding assays at human cloned alpha 1-adrenoreceptor (alpha 1-AR) subtypes and 5-HT 1A receptors, expressed in Chinese hamster ovary and HeLa cell membranes, respectively, and by functional experiments in isolated rat vas deferens (alpha 1A), spleen (alpha 1B), and aorta (alpha 1D). Moreover, the cytotoxic effects of the novel compounds were determined in PC-3 prostate cancer cells. The results showed that the properly substituted 1,4-dioxane nucleus proved to be a suitable scaffold for selective alpha 1D-AR antagonists (compound 14), potential anticancer agents (compound 13), and full 5-HT 1A receptor agonists (compound 15). In particular, compound 15 may represent a novel lead in the development of highly potent 5-HT 1A receptor full agonists useful as antidepressant and neuroprotective agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817363     DOI: 10.1021/jm800461k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Heterocycles via intramolecular platinum-catalyzed propargylic substitution.

Authors:  Qiren Liang; Jef K De Brabander
Journal:  Tetrahedron       Date:  2011-07-08       Impact factor: 2.457

2.  Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.

Authors:  Fabio Del Bello; Eleonora Diamanti; Mario Giannella; Valerio Mammoli; Laura Mattioli; Federica Titomanlio; Alessandro Piergentili; Wilma Quaglia; Marco Lanza; Chiara Sabatini; Gianfranco Caselli; Elena Poggesi; Maria Pigini
Journal:  ACS Med Chem Lett       Date:  2013-07-22       Impact factor: 4.345

3.  Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect.

Authors:  Fabio Del Bello; Eleonora Diamanti; Mario Giannella; Valerio Mammoli; Carla Marchioro; Laura Mattioli; Federica Titomanlio; Alessandro Piergentili; Wilma Quaglia; Giovanni Benedetti; Maurizio Varrone; Maria Pigini
Journal:  ACS Med Chem Lett       Date:  2012-06-08       Impact factor: 4.345

4.  Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment.

Authors:  Xin Zhao; Minsheng Chen; Biyun Huang; Hong Ji; Mu Yuan
Journal:  Int J Mol Sci       Date:  2011-10-20       Impact factor: 5.923

5.  Characterization of an Indole-3-Acetamide Hydrolase from Alcaligenes faecalis subsp. parafaecalis and Its Application in Efficient Preparation of Both Enantiomers of Chiral Building Block 2,3-Dihydro-1,4-Benzodioxin-2-Carboxylic Acid.

Authors:  Pradeep Mishra; Suneet Kaur; Amar Nath Sharma; Ravinder S Jolly
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

6.  Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus.

Authors:  Fabio Del Bello; Alessandro Bonifazi; Gianfabio Giorgioni; Alessandro Piergentili; Maria Giovanna Sabbieti; Dimitrios Agas; Marzia Dell'Aera; Rosanna Matucci; Marcin Górecki; Gennaro Pescitelli; Giulio Vistoli; Wilma Quaglia
Journal:  J Med Chem       Date:  2020-05-19       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.